Overview
Technologies
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Total raised
$64.4M
4 rounds on record
Latest round
$20M
Venture round · May 2024 · 2 yr ago
Team
85
US Form 5500 (plan participants) · Dec 2025 · +6% in a year
Hiring now
1
open roles
The money's age
Long since its last round
28 months since the last round · hiring slowed
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 24, 2024 Raised a round Venture round $20M · SEC Form D Oct 13, 2023 Took on debt financing $35M · SEC Form D Oct 18, 2021 Raised a round Venture round $41.9M · SEC Form D Mar 14, 2019 Raised a round Venture round $2.5M · SEC Form D
Funding rounds
RoundDateAmountInvestorsSource
Venture round May 2024 $20M — SEC Form D
Debt Financing Oct 2023 $35M — SEC Form D
Venture round Oct 2021 $41.9M — SEC Form D
Venture round Mar 2019 $2.5M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Bionano Genomics, Inc SEC Form D
Founders and leadersfrom filings, registers and the company's site
R. Erik Holmlin Ph.D.Executive Officer, DirectorSEC Form D
Warren RobinsonExecutive OfficerSEC Form D
Mike WardExecutive OfficerSEC Form D
Mark BorodkinExecutive OfficerSEC Form D
Soheil ShamsExecutive OfficerSEC Form D
Richard ShippyExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
PhasegenomicsVenture round $4.8M · 3 yr ago • Founded 2015 • 11-50 employees
Phase Genomics: Fueling Genomic Discovery. CytoTerra® Cytogenetics, ProxiMeta™ Metagenome Deconvolution, Proximo™ Genome Scaffolding.
The next generation of genome-wide on- and off-target analysis in your own hands. Our INDUCE-seq platform provides precise off-target…
Gamow Labs11-50 employees
Sequencing is solved. Interpretation is the bottleneck. Gamow Labs is building the AI-native approach that turns genomes and phenotypes…
Screen embryos for 400+ genetic conditions before pregnancy. Orchid's whole genome screening reads 99% of an embryo's genome — 100x more…
InocrasFounded 2020
Unlock the potential of a Whole Genome Sequencing Test with Inocras. Transforming diagnosis and treatment for cancer and rare diseases.
MyOme is a clinical whole genome analysis platform company helping families understand their risk for inherited diseases. As a leader in…

Visa sponsorship

  • United States · green card filings: 1

Visa details by country

Overview

Discover how Bionano is striving to elevate health and wellness for all through optical genome mapping (OGM) solutions that transform the way the world sees the genome.

Tech stack

Technologies named in job postings at Bionano over the last 12 months, by layer, with the share of postings for each.
Technologies in use
1
Postings analysed
1
Stack modernity
85/100
Cloud & platforms
Linux
Sign in to see how your skills match this stack Sign In

People

R. Erik Holmlin Ph.D.
Executive Officer, Director
Warren Robinson
Executive Officer
Mike Ward
Executive Officer
Mark Borodkin
Executive Officer
Soheil Shams
Executive Officer
Richard Shippy
Executive Officer
Alka Chaubey Ph.D. FACMG
Executive Officer
Christopher Stewart
Executive Officer
Jason Priar
Executive Officer
Mark Oldakowski
Executive Officer
Gulsen Kama
Executive Officer
R. Holmlin
Executive Officer, Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Growth

Hiring Momentum
28/100
Slowing
Open positions
1
0 opened / 0 closed in 30 days
ATS activity
Every ~3 hours
Today
Hiring Dynamics 0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Field & Service
100% ▲

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
San Diego United States
HQ
500-1000 est. staff

Financials

Total raised
$99.4M
Latest round
Venture - Series Unknown
Funding rounds
4
Funding rounds
Round Announced Amount
Venture - Series Unknown 2024 $20M Details
Debt Financing 2023 $35M Details
Venture - Series Unknown 2021 $41.9M Details
Venture - Series Unknown 2019 $2.5M Details